Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. reports a material definitive agreement entered into on March 27, 2014, and filed on April 2, 2014. The Company, headquartered in Cambridge, Massachusetts, operates in the biopharmaceutical sector.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a real estate lease amendment.
Material Changes
The primary material change is the execution of a Fifth Amendment to the Company's lease agreement with ARE-MA Region No. 28, LLC for its corporate headquarters at 300 Third Street, Cambridge, Massachusetts.
- Lease Extension: The Company exercised an option to extend the lease term for an additional five years, moving the expiration date from September 2016 to September 30, 2021.
- Future Option: The amended agreement grants the Company the option to extend the lease for one additional five-year term beyond 2021.
- Property Details: The lease covers approximately 129,000 square feet of office and laboratory space.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific risk factors beyond the commitment to the extended lease term. No unusual items or contingencies are disclosed in this report.
Investor Verification Points
- Verify the total financial impact of the lease extension on future operating expenses and cash flow commitments.
- Confirm the specific terms of the optional five-year extension beyond 2021, including any rent adjustments.
- Review the Company's capital allocation strategy to ensure the extended lease aligns with long-term operational needs.